United States

People: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

17 Feb 2017
Change (% chg)

$0.78 (+0.66%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Stoffels, Paulus 

Dr. Paulus A. Stoffels is Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group of Johnson & Johnson. He joined the Company in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec. In 2005, he was appointed Company Group Chairman, Global Virology where he led the development of PREZISTA® and INTELENCE®, leading products for the treatment of HIV. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the Central Nervous System and Internal Medicine Franchises. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals, in 2009, and in 2011 became Worldwide Chairman, Pharmaceuticals, with responsibility for the Company's therapeutic pipeline through global research and development and strategic business development. In 2012, Dr. Stoffels was also appointed Chief Scientific Officer, with responsibility for enterprise-wide innovation and product safety, and a Member of the Executive Committee. He Provided strong leadership within the Pharmaceutical Research & Development organization, as evidenced by the significant growth of our Pharmaceutical pipeline.

Basic Compensation

Total Annual Compensation, USD 3,330,480
Restricted Stock Awards, USD 4,208,870
Long-Term Incentive Plans, USD --
All Other, USD 3,246,390
Fiscal Year Total, USD 10,785,700

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Alex Gorsky


Dominic Caruso


Sandra Peterson


Paulus Stoffels


Michael Ullmann


Peter Fasolo

As Of  2 Jan 2016